Reference number : GC-2017-Q3-00560, amendment number : , agreement type : G, recipient legal name : Delisle, Jean-Sébastien (Université de Montréal), recipient country : CA, recipient province : nan, recipient city : Quebec|Québec, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : Recent advances in biotechnology allow for the genetic modification of animal and human cells for_x000D_
applications in research and medicine. This field is extremely promising and is likely to change how research is_x000D_
performed and how therapies are designed in the future, notably by using cells as medicines. This might be_x000D_
especially true for T cells, a subset of immune cells capable to fight refractory infections and certain cancers._x000D_
This project matches a novel approach to genetically engineer cells (developed by Feldan, a biotechnology_x000D_
company) with the T-cell handling expertise developed at the University of Montréal. Specifically, the_x000D_
principal objective of this application is to develop and validate the best method to genetically engineer T cells_x000D_
using a Feldan product; the Shuttle. The Shuttle allows for the delivery of a cargo within the nucleus of the cell,_x000D_
where the genetic material is located. This transport is non-traumatic to the cell and as such may represent a_x000D_
marked advantage compared to competing approaches in the field. We will thus use the Shuttle to carry_x000D_
proteins capable to precisely modify the genetic code of cells (commonly referred as the CRISPR/Cas9_x000D_
system). Although the Shuttle can be used to genetically engineer several cell types, Feldan has no experience_x000D_
using it in T cells. The Delisle laboratory at the University of Montréal will provide this expertise and benefit_x000D_
from the Shuttle technology to advance the development of T-cell research. The project has two main aims;_x000D_
1-to optimize Shuttle-based cargo transfer methods to the nucleus of T cells in culture and 2- to provide a_x000D_
proof-of-principle of genetic editing in T cells. This work will enable Feldan and the Delisle laboratory to_x000D_
obtain key data to leverage additional funding towards the goal of positioning the Shuttle technology in the_x000D_
expanding field of T-cell editing., program purpose french : Recent advances in biotechnology allow for the genetic modification of animal and human cells for_x000D_
applications in research and medicine. This field is extremely promising and is likely to change how research is_x000D_
performed and how therapies are designed in the future, notably by using cells as medicines. This might be_x000D_
especially true for T cells, a subset of immune cells capable to fight refractory infections and certain cancers._x000D_
This project matches a novel approach to genetically engineer cells (developed by Feldan, a biotechnology_x000D_
company) with the T-cell handling expertise developed at the University of Montréal. Specifically, the_x000D_
principal objective of this application is to develop and validate the best method to genetically engineer T cells_x000D_
using a Feldan product; the Shuttle. The Shuttle allows for the delivery of a cargo within the nucleus of the cell,_x000D_
where the genetic material is located. This transport is non-traumatic to the cell and as such may represent a_x000D_
marked advantage compared to competing approaches in the field. We will thus use the Shuttle to carry_x000D_
proteins capable to precisely modify the genetic code of cells (commonly referred as the CRISPR/Cas9_x000D_
system). Although the Shuttle can be used to genetically engineer several cell types, Feldan has no experience_x000D_
using it in T cells. The Delisle laboratory at the University of Montréal will provide this expertise and benefit_x000D_
from the Shuttle technology to advance the development of T-cell research. The project has two main aims;_x000D_
1-to optimize Shuttle-based cargo transfer methods to the nucleus of T cells in culture and 2- to provide a_x000D_
proof-of-principle of genetic editing in T cells. This work will enable Feldan and the Delisle laboratory to_x000D_
obtain key data to leverage additional funding towards the goal of positioning the Shuttle technology in the_x000D_
expanding field of T-cell editing., agreement title english : Novel approach for T-cell genetic editing, agreement title french : Novel approach for T-cell genetic editing, agreement number : EGP, agreement value : 25000.0, agreement start date : 2017-11-08, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada